Skip to main content

Table 1 Baseline patient demographics and disease characteristics

From: A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

  CT-P13 3 mg/kg (n = 302) RP 3 mg/kg (n = 304) Total (N = 606)
Age, median, years (range) 50 (18–75) 50 (21–74) 50 (18–75)
 Sex, n (%)    
 Female 245 (81.1) 256 (84.2) 501 (82.7)
 Male 57 (18.9) 48 (15.8) 105 (17.3)
Ethnicity, n (%)    
 Asian 34 (11.3) 37 (12.2) 71 (11.7)
 Black 2 (0.7) 1 (0.3) 3 (0.5)
 White 220 (72.8) 222 (73.0) 442 (72.9)
 Other 46 (15.2) 44 (14.5) 90 (14.9)
Height, cm, median (range) 162.3 (144.0–186.0) 162.0 (124.0–190.0) 162.0 (124.0–190.0)
Weight, kg, median (range) 69.0 (36.5–134.0) 68.0 (36.0–136.0) 68.6 (36.0–136.0)
BMI, kg/m2, median (range) 26.3 (13.9–49.8) 25.4 (15.0–53.1) 25.9 (13.9–53.1)
Anti-CCP antibody-positive, n (%) 228 (75.5) 233 (76.6) 461 (76.1)
IgA RF-positive, n (%) 131 (43.4) 134 (44.1) 265 (43.7)
IgM RF-positive, n (%) 225 (74.5) 220 (72.4) 445 (73.4)
IgG RF-positive, n (%) 173 (57.3) 171 (56.3) 344 (56.8)
Joint count    
 TJC, 68 joints 25.6 ± 13.9 24.0 ± 12.9 24.8 ± 13.4
 SJC, 66 joints 16.2 ± 8.7 15.2 ± 8.3 15.7 ± 8.5
 TJC, 28 joints 15.9 ± 6.4 15.1 ± 6.1 15.5 ± 6.2
 SJC, 28 joints 12.0 ± 4.9 11.2 ± 4.7 11.6 ± 4.8
Duration of prior MTX therapy, weeks 97.7 ± 141.2 89.4 ± 96.5 93.6 ± 120.8
MTX dose, mg 15.6 ± 3.1 15.6 ± 3.2 15.6 ± 3.1
CDAI 40.9 ± 11.5 39.3 ± 11.1 40.1 ± 11.3
SDAI 42.8 ± 11.9 41.2 ± 11.7 42.0 ± 11.8
CRP, mg/dl 1.9 ± 2.5 1.9 ± 2.2 1.9 ± 2.4
ESR, mm/h 46.6 ± 22.4 48.5 ± 22.6 47.5 ± 22.5
DAS28-CRP 5.9 ± 0.8 5.8 ± 0.9 5.8 ± 0.9
HAQ 1.6 ± 0.6 1.6 ± 0.6 1.6 ± 0.6
Patient assessment of pain 65.9 ± 17.4 65.5 ± 17.2 65.7 ± 17.3
Patient global assessment of disease activity 65.7 ± 17.2 65.4 ± 17.0 65.5 ± 17.1
Physician global assessment of disease activity 64.7 ± 14.3 65.0 ± 13.5 64.8 ± 13.9
  1. BMI body mass index, CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, Ig immunoglobulin, MTX methotrexate, RF rheumatoid factor, RP reference product (i.e., reference infliximab), SD standard deviation, SDAI Simplified Disease Activity Index, SJC swollen joint count, TJC tender joint count
  2. Except where indicated otherwise, values are mean ± SD